This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caro, J. J.
Right arrow Articles by Payne, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caro, J. J.
Right arrow Articles by Payne, K.
Related Collections
Right arrow Drugs: cardiovascular system
Right arrow Other evidence-based medicine
CMAJ • January 25, 2000; 162 (2)
© 2000 Canadian Medical Association or its licensors

Letters
Correspondance

Real-world effectiveness of antihypertensive drugs

J. Jaime Caro and Krista Payne

Caro Research; Montreal, Que.

James Wright and colleagues reported results of a meta-analysis of data on the effects of various antihypertensive drugs.1 Their stated purpose was to assist physicians in choosing an initial antihypertensive drug by systematically quantifying the available evidence on efficacy, defined as lowering blood pressure and preventing adverse outcomes. They did not achieve this goal, however, because they focused exclusively on clinical trial data. Although they mentioned the importance of exercising treatment decisions on the basis of the best available evidence, they failed to remind physicians that the real-world effectiveness of antihypertensive therapies is also largely a function of patient compliance. Unfortunately, although Wright and colleagues included data for study withdrawals, they did not consider that real-world compliance cannot be studied under the conditions imposed by trials.2

If they had deemed results from studies that investigated compliance with antihypertensive therapies in actual practice as additional evidence worthy of consideration, physicians would also have been informed that class-specific patterns of persistence with initial antihypertensive drug therapy have emerged.3-6 Persistence with antihypertensive therapy, for example, is generally poor, particularly for initial therapy with older agents such as diuretics and ß-blockers. Therefore, to conclude, as the authors have, that physicians should select a diuretic in the absence of contraindications ignores the best available evidence. If the ultimate goal of antihypertensive therapy is to control hypertension and to avoid cardiovascular events, then physicians must consider all available evidence. An anti-hypertensive medication is only efficacious if a patient remains on therapy, and initial choice of antihypertensive therapy appears to be a significant factor in achieving this outcome.

References

  1. Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug? CMAJ 1999;161(1):25-32.[Abstract/Free Full Text]
  2. Pablos-Mendéz A, Barr G, Shea S. Run-in periods in randomized trials. JAMA 1998;279:222-5.[Abstract/Free Full Text]
  3. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-5.[Abstract/Free Full Text]
  4. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Ajorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997;10(7):697-704.[Medline]
  5. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160(1):31-7.[Abstract]
  6. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160(1):41-6.[Abstract]



This article has been cited by other articles:


Home page
 CMAJHome page
J. J. Caro and K. Payne
The value of industry-sponsored studies of initial antihypertensive therapies
Can. Med. Assoc. J., June 1, 2001; 164(13): 1832 - 1832.
[Full Text] [PDF]

Home page
 CMAJHome page
J. M. Wright
The value of industry-sponsored studies of initial antihypertensive therapies
Can. Med. Assoc. J., June 1, 2001; 164(13): 1832 - 1833.
[Full Text]

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caro, J. J.
Right arrow Articles by Payne, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caro, J. J.
Right arrow Articles by Payne, K.
Related Collections
Right arrow Drugs: cardiovascular system
Right arrow Other evidence-based medicine